Business Wire

THE-BRAIN-FORUM

7.4.2016 11:11:51 CEST | Business Wire | Press release

Share
Lausanne to Be the Epicentre of Brain Research in May 2016

The Brain Forum brings together top scientists and entrepreneurs from the world’s biggest brain initiatives. The event will run in collaboration with EPFL on 26 and 27 May at the SwissTech Convention Center in Lausanne, Switzerland.

Launched in 2013, The Brain Forum plays an important role in the progression of brain research by connecting researchers, engineers, healthcare professionals, entrepreneurs, investors, funding agencies and policy makers. In so doing, The Brain Forum helps to accelerate our understanding of the brain by translating science from bench to business, thus making laboratory innovations available to all.

Dr. Jamil El-Imad, CEO of The Brain Forum, comments: “We want to include anyone with an interest in the brain. We hope that our different but complementary experience and perspectives can help to overcome the biggest challenges of this era. You can’t build the future based on present assumptions so we need to develop our thinking and be open to spontaneous opportunities that may lead to the necessary serendipity for innovation.”

The Brain Forum has proven a great success in previous years. This year the main objectives are to enhance the attendance of the international community, to promote awareness of brain science at a global level and to stimulate worldwide, unified efforts to tackle one of the biggest healthcare challenges of this century. The event features an impressive line-up of world-renowned experts who promise to give fascinating insights into cutting-edge research, advancements in our understanding of the brain and the impact of that knowledge. International brain initiatives and regulatory bodies from the EU, USA, Japan and China will share how they are working towards improving brain research. Google will host a special session on ‘Lessons from practical machine intelligence’ followed by UBS on ‘The Workforce of the Future,’ while the popular start-up competition returns offering opportunities for start-ups to pitch to investors looking to invest in the solutions of the future.

The Brain Forum was created because scientific exploration of the brain is fundamental for tackling the challenges of the 21st century. As more and more people are affected by neurological and psychiatric conditions, there is increasing awareness of the importance of brain research to healthcare and technology. WHO recently concluded that brain disorders account for 35 per cent of the burden of all diseases in Europe and will become the major medical need of this century. In 2010, the European Brain Council published a report demonstrating that brain disorders cost Europe EUR 800 billion in 2010 – more than cardiovascular disease, cancer and diabetes combined.

Dr. El-Imad adds: “The future is both terrific and terrifying. Our aging populations are increasing the incidence and burden of many neurological and psychiatric diseases presenting huge challenges for healthcare and society, while artificial intelligence will presage a new industrial revolution, altering the workforce of the future and shifting further the balance of humans vs. machines. Technology and science will allow us to do things that we never imagined possible, but we as a society need to be prepared to deal with the consequences – good and bad – of our rapidly changing future.”

To participate - and mould the future of brain science – register at:
www.thebrainforum.org

*Source: ME NewsWire

Contact:

Headline office
The Brain Forum
Christophe Tournier, press office, +412-1517-6717
thebrainforum@farner.ch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release

Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw

Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 02:00:00 CEST | Press release

Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release

Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye